Immunological alterations after immunotherapy with short lived HBV‐TCR T cells associates with long‐term treatment response in HBV‐HCC

Anthony Tanoto Tan, Fanping Meng, Jiehua Jin, Ji‐Yuan Zhang, Si‐Yu Wang, Lei Shi, Ming Shi, Yuanyuan Li, Yunbo Xie, Li‐Min Liu, Chun‐Bao Zhou, Alicia Chua, Zi Zong Ho, Junqing Luan, Jinfang Zhao, Jing Li, Lu‐En Wai, Sarene Koh, Tingting Wang, Antonio Bertoletti, Fu‐sheng Wang – 20 December 2021 – The application of hepatitis B virus (HBV)–T‐cell receptor (TCR) T‐cell immunotherapy in patients with HBV‐related hepatocellular carcinoma (HBV‐HCC) has been apathetic, as the expression of HBV antigens by both normal HBV‐infected hepatocytes and HCC cells with HBV‐DNA integration increases the ri

Loss of bile salt export pump aggravates lipopolysaccharide‐induced liver injury in mice due to impaired hepatic endotoxin clearance

Jelena Remetic, Ahmed Ghallab, Zaynab Hobloss, Lisa Brackhagen, Reham Hassan, Maiju Myllys, Richard Radun, Veronika Mlitz, Ci Zhu, Maximilian Baumgartner, Waltraud C. Schrottmaier, Marion Mussbacher, Gerald Timelthaler, Hubert Scharnagl, Tatjana Stojakovic, Alice Assinger, Claudia D. Fuchs, Jan G. Hengstler, Michael Trauner – 19 December 2021

Lower Alpha‐Fetoprotein Threshold of 500 ng/mL for Liver Transplantation May Improve Posttransplant Outcomes in Patients With Hepatocellular Carcinoma

Max L. Goldman, Kali Zhou, Jennifer L. Dodge, Francis Yao, Neil Mehta – 19 December 2021 – Under current United Network for Organ Sharing (UNOS) policy, patients with hepatocellular carcinoma (HCC) and alpha‐fetoprotein (AFP) levels ≥1000 ng/mL are required to show a reduction in AFP level to <500 ng/mL before liver transplantation (LT). However, effects of AFP reduction on post‐LT HCC outcomes among patients with HCC with moderately elevated AFP levels between 100 and <1000 ng/mL are unclear.

Alcohol Consumption and Cardiovascular Outcomes in Patients With Nonalcoholic Fatty Liver Disease: A Population‐Based Cohort Study

Malik Janjua, Matthew Knuiman, Mark Divitini, Brendan McQuillan, John K. Olynyk, Gary P. Jeffrey, Leon A. Adams – 19 December 2021 – Low‐level alcohol consumption is associated with reduced cardiovascular disease (CVD) in the general population. It is unclear whether this association is seen in patients with nonalcoholic fatty liver disease (NAFLD) who have an increased risk of CVD. We examined the association between alcohol consumption and CVD‐related outcomes in subjects with NAFLD from a general population cohort.

Subscribe to